FDA commissioner pledges to investigate mifepristone
The Hill
BY ALEJANDRA O’CONNELL-DOMENECH
Food and Drug Administration Commissioner Marty Makary committed to reviewing the abortion drug mifepristone in a letter sent to Senator Josh Hawley (R-Mo.).
“As with all drugs, FDA continues to closely monitor the postmarketing safety data on mifepristone for the medical termination of early pregnancy,” Makary wrote to Hawley.
“As the Commissioner of Food and Drugs, I am committed to conducting a review of mifepristone and working with the professional career scientists at the Agency who review this data,” he added in the letter.
Makary did not provide any further details about the forthcoming review since the abortion drug is a part of ongoing litigation.